Adhera Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000149315223010160 Filed on March 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.00K $32.00K $32.00K
YoY Change 72.5% -57.89% -57.89%
Cash & Equivalents $69.00K $32.00K
Short-Term Investments
Other Short-Term Assets $35.00K $47.00K $47.00K
YoY Change -73.08% -60.83% -60.83%
Inventory
Prepaid Expenses $35.00K $47.00K
Receivables
Other Receivables
Total Short-Term Assets $104.0K $79.00K $79.00K
YoY Change -38.82% -59.69% -59.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $104.0K $79.00K $79.00K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $104.0K $79.00K $79.00K
YoY Change -38.82% -59.69% -59.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.410M $2.397M $2.397M
YoY Change 5.38% 3.81% 3.81%
Accrued Expenses $4.725M $4.373M $4.373M
YoY Change 36.28% 40.61% 40.61%
Deferred Revenue
YoY Change
Short-Term Debt $1.228M $1.252M $1.252M
YoY Change 6.69% 26.98% 26.98%
Long-Term Debt Due $8.398M $7.333M $7.333M
YoY Change 47.93% 29.17% 29.17%
Total Short-Term Liabilities $23.20M $22.27M $22.27M
YoY Change -9.63% -12.0% -12.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $23.20M $22.27M $22.27M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $23.20M $22.27M $22.27M
YoY Change -9.63% -12.0% -12.0%
SHAREHOLDERS EQUITY
Retained Earnings -$56.70M -$55.80M
YoY Change 5.25%
Common Stock $19.00K $19.00K
YoY Change -81.37%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.000K $2.000K
YoY Change
Treasury Stock Shares 5.594K shares
Shareholders Equity -$23.10M -$22.20M -$22.19M
YoY Change
Total Liabilities & Shareholders Equity $104.0K $79.00K $79.00K
YoY Change -38.82% -59.69% -59.69%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000737207
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 atrx Reclassification Of Derivative Liability
ReclassificationOfDerivativeLiability
usd
CY2020Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
usd
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
usd
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesCurrent
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
usd
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 atrx Income Tax Actual Provision
IncomeTaxActualProvision
usd
CY2021 atrx Income Tax Actual Provision
IncomeTaxActualProvision
usd
CY2022 atrx Income Tax Expense Benefit Difference
IncomeTaxExpenseBenefitDifference
usd
CY2021 atrx Income Tax Expense Benefit Difference
IncomeTaxExpenseBenefitDifference
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-13789
CY2022 dei Entity Registrant Name
EntityRegistrantName
ADHERA THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2658569
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
8000 Innovation Parkway
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70820
CY2022 dei City Area Code
CityAreaCode
(919)
CY2022 dei Local Phone Number
LocalPhoneNumber
518-3748
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
3100000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3178738 shares
CY2022 dei Auditor Firm
AuditorFirmId
106
CY2022 dei Auditor Name
AuditorName
SALBERG & COMPANY, P.A.
CY2022 dei Auditor Location
AuditorLocation
Boca Raton, Florida
CY2022Q4 us-gaap Cash
Cash
32000 usd
CY2021Q4 us-gaap Cash
Cash
76000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
120000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
196000 usd
CY2022Q4 us-gaap Assets
Assets
79000 usd
CY2021Q4 us-gaap Assets
Assets
196000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2397000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2309000 usd
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
26000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
46000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4373000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3110000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
498000 usd
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
5477000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7333000 usd
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5677000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
986000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6386000 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7697000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22265000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25302000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22265000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
25302000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3160877 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3160877 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
853946 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
853946 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33548000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27906000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55751000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53017000 usd
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5594 shares
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25106000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
196000 usd
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1618000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
657000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
1618000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
674000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1618000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-674000 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
1344000 usd
CY2021 us-gaap Interest Expense Other
InterestExpenseOther
1035000 usd
CY2022 atrx Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
2324000 usd
CY2021 atrx Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
-4103000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
333000 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-141000 usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1809000 usd
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
398000 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-496000 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5677000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2114000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6351000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2114000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6351000 usd
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
620000 usd
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2054000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2734000 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8405000 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.84
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2307534 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
654700 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-14740000 usd
CY2021 us-gaap Dividends
Dividends
1513000 usd
CY2021 atrx Adjustments To Additional Paid In Capital Reclassification Of Derivative
AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivative
-3462000 usd
CY2021 atrx Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
-1000 usd
CY2021 atrx Stock Issued During Period Value Conversion With Convertible Note
StockIssuedDuringPeriodValueConversionWithConvertibleNote
316000 usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
535000 usd
CY2021 atrx Stock Issued During Period Value Conversion Of Series E Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesEPreferredStockForCommonStock
3000 usd
CY2021 atrx Stock Issued During Period Value Conversion Of Series F Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesFPreferredStockForCommonStock
107000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6351000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25106000 usd
CY2022 us-gaap Dividends
Dividends
620000 usd
CY2022 atrx Stock Issued During Period Value Conversion With Convertible Note
StockIssuedDuringPeriodValueConversionWithConvertibleNote
18000 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
28000 usd
CY2022 atrx Stock Issued During Period Value Issuance Of Common Stock With Term Loan
StockIssuedDuringPeriodValueIssuanceOfCommonStockWithTermLoan
11000 usd
CY2022 atrx Stock Issued During Period Value Conversion Of Series E Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesEPreferredStockForCommonStock
5056000 usd
CY2022 atrx Stock Issued During Period Value Conversion Of Series F Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesFPreferredStockForCommonStock
543000 usd
CY2022 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2114000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2114000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6351000 usd
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1809000 usd
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
398000 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
1344000 usd
CY2021 us-gaap Interest Expense Other
InterestExpenseOther
1035000 usd
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2324000 usd
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-4103000 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
333000 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-141000 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-73000 usd
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
120000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
68000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
94000 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
62000 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
35000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1415000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-665000 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2300000 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
840000 usd
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
346000 usd
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
101000 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000 usd
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
581000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1371000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
739000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76000 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
94000 usd
CY2022 atrx Issuance Of Common Stock For Conversion Of Series E Preferred
IssuanceOfCommonStockForConversionOfSeriesEPreferred
5056000 usd
CY2021 atrx Issuance Of Common Stock For Conversion Of Series E Preferred
IssuanceOfCommonStockForConversionOfSeriesEPreferred
116000 usd
CY2022 atrx Issuance Of Common Stock For Conversion Of Series F Preferred
IssuanceOfCommonStockForConversionOfSeriesFPreferred
543000 usd
CY2021 atrx Issuance Of Common Stock For Conversion Of Series F Preferred
IssuanceOfCommonStockForConversionOfSeriesFPreferred
3000 usd
CY2022 atrx Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
20000 usd
CY2021 atrx Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
320000 usd
CY2022 us-gaap Stock Issued1
StockIssued1
554000 usd
CY2021 us-gaap Stock Issued1
StockIssued1
554000 usd
CY2021 atrx Reclassification Of Derivative Liability
ReclassificationOfDerivativeLiability
3462000 usd
CY2022 atrx Accrued And Deemed Dividends
AccruedAndDeemedDividends
620000 usd
CY2021 atrx Accrued And Deemed Dividends
AccruedAndDeemedDividends
2054000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32000 usd
CY2022Q4 atrx Working Capital
WorkingCapital
22200000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2100000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1400000 usd
CY2022Q4 atrx Working Capital
WorkingCapital
22200000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22200000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55800000 usd
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
361000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
32000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zysexMfegW0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zzyC4yILw6za">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
0 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7697000 usd
CY2021Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
7697000 usd
CY2021 atrx Initial Valuation Of Derivative Liabilities Included In Debt Discount
InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount
377000 usd
CY2021 atrx Initial Valuation Of Derivative Liabilities Included In Derivative Expense
InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense
1594000 usd
CY2021 atrx Reclassification Of Derivative Liabilities To Gain On Debt Extinguishment
ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment
-245000 usd
CY2021 atrx Reclassification Of Additional Paid In Capital
ReclassificationOfAdditionalPaidInCapital
3462000 usd
CY2021 atrx Change In Fair Value Included In Derivative Expense
ChangeInFairValueIncludedInDerivativeExpense
2509000 usd
CY2021Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
7697000 usd
CY2022Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
0 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6386000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
6386000 usd
CY2021Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
7697000 usd
CY2022 atrx Initial Valuation Of Derivative Liabilities Included In Debt Discount
InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount
1365000 usd
CY2022 atrx Initial Valuation Of Derivative Liabilities Included In Derivative Expense
InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense
191000 usd
CY2022 atrx Reclassification Of Derivative Liabilities To Gain On Debt Extinguishment
ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment
351000 usd
CY2022 atrx Change In Fair Value Included In Derivative Expense
ChangeInFairValueIncludedInDerivativeExpense
2516000 usd
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
6386 usd
CY2021Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1516000 usd
CY2022Q4 atrx Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
67000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2114000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6351000 usd
CY2022 us-gaap Dividends Preferred Stock
DividendsPreferredStock
620000 usd
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2054000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2734000 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8405000 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2307534 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
654700 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.84
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11281030 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8580979 shares
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
47000 usd
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
120000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
8042000 usd
CY2021Q4 us-gaap Notes Payable
NotesPayable
5677000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
709000 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
7333000 usd
CY2021Q4 us-gaap Loans Payable
LoansPayable
5677000 usd
CY2022Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
(i) the 12-month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
CY2021Q4 atrx Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
530000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1319000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6785914 shares
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
986000 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
77330 usd
CY2022Q1 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.16 pure
CY2022Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.18 pure
CY2022Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
32000 usd
CY2021 atrx Reclassification Of Additional Paid In Capital To Derivative Liability
ReclassificationOfAdditionalPaidInCapitalToDerivativeLiability
3462000 usd
CY2022Q4 atrx Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2021Q4 atrx Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2022Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
4000 usd
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
4000 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6785914 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2022 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1651718 shares
CY2022 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
1269649 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3731263 shares
CY2022 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
133284 shares
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1700000 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19568 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.00
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
365 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
36.60
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19203 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.40
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
203 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
34.00
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.60
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
19000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.60
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
19000 shares
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P0Y3M29D
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
19.60
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
19000 shares
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
19.60
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
320000000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
7700000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7658000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8402000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
8522000 usd
CY2022Q4 atrx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1170000 usd
CY2021Q4 atrx Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1272000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
683000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
647000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1251000 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
613000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19284000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10935000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18991000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10935000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
293000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022 atrx Income Tax Pretax Income Loss
IncomeTaxPretaxIncomeLoss
-2113769 usd
CY2021 atrx Income Tax Pretax Income Loss
IncomeTaxPretaxIncomeLoss
-6351000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-443891 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1333710 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-637312 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.3015 pure
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-808346 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.1273 pure
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-6981657 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
3.3029 pure
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
515587 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0812 pure
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
133836 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0633 pure
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1095551 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.1725 pure
CY2022 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-125241 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
0.0593 pure
CY2021 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
-301037 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
0.0474 pure
CY2022 atrx Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance State
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowanceState
-1153652 usd
CY2022 atrx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance State
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceState
0.5458 pure
CY2021 atrx Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance State
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowanceState
932558 usd
CY2021 atrx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance State
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceState
-0.1468 pure
CY2022 atrx Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Federal
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowanceFederal
9207918 usd
CY2022 atrx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Federal
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceFederal
-4.3562 pure
CY2021 atrx Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Federal
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowanceFederal
-100602 usd
CY2021 atrx Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Federal
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceFederal
0.0158 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8000000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
42000000000 usd

Files In Submission

Name View Source Status
0001493152-23-010160-index-headers.html Edgar Link pending
0001493152-23-010160-index.html Edgar Link pending
0001493152-23-010160.txt Edgar Link pending
0001493152-23-010160-xbrl.zip Edgar Link pending
atrx-20221231.xsd Edgar Link pending
aud_001.jpg Edgar Link pending
ex21-1.htm Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_001.jpg Edgar Link pending
form10-k_002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
atrx-20221231_cal.xml Edgar Link unprocessable
atrx-20221231_def.xml Edgar Link unprocessable
atrx-20221231_lab.xml Edgar Link unprocessable
atrx-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending